Acadia gets more rights for Daybue, forking over $100M upfront after an ‘impressive’ US launch
Acadia Pharmaceuticals is acquiring further rights to Neuren Pharmaceuticals’ newly approved Rett syndrome treatment for $100 million amid a better-than-expected launch of the drug.
The deal, announced Thursday, expands on a licensing agreement first set up in 2018 and deepens Acadia’s position in rare disease.
It will see Acadia get the ex-North American rights to Daybue, also known as trofinetide, which earned FDA approval in March and went on the market in April. Acadia also obtained the global rights to Neuren’s NNZ-2591, which is being tested as a treatment for Rett syndrome and Fragile X syndrome, a common cause of autism, and four other neurodevelopmental syndromes.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
